Furthermore, BRCA2 mutation/deletion is far more common in prostate cancer than BRCA1 loss of function, whereas in breast cancer, the relative frequencies on BRCA1 versus BRCA2 mutation are nearly equal (1). This evidence concerns the gene BRCA2 and prostate cancer.